BASF custom synthesis business has been unaffected by the global economic uncertainty. “In general we see this as a growing market,” says Folker Ruchatz, v.p./global business management custom synthesis at BASF. The company is experiencing “steady growth” in activities relating to generic APIs, with “stronger growth” for excipients, especially in high-performance and innovative products. The company also is experiencing “strong demand” in custom synthesis, where Ruchatz predicts BASF “will grow faster than the market. We have a positive outlook for 2012,” he says. Although BASF doesn’t split out the financial performance of its pharmaceutical fine chemicals activities the business is among the top-10 players in the world, Ruchatz says.

Codexis (Redwood City, CA), an enzymes technology firm, since 2010 has increased its pharma customers from about 15 to about 50. In part this growth has come about because the company has changed its patent position by allowing its customers to patent processes using Codexis’s insights. The growth is also down to a greater acceptance across the pharma industry of using biocatalysis, says Peter Seufer-Wasserthal, v.p. and managing director/pharma services for Codexis. “Financials are good, the order book is on the full side,” Seufer-Wasserthal says.

Halocarbon (River Edge, NJ),a fluorochemicals pure play, also is experiencing year-on-year growth and is optimistic about its prospects for 2012. Quality is pinpointed by the company as a factor that is contributing to its growth. An illustration of its quality management is the company decision to appoint a dedicated inspector of labels on products. The company photographs every shipment of a product so that it knows that the product is going out in good order. “This [kind of] a detail we feel is being recognized,” says Ron Epstein, director/sales for Halocarbon. Halocarbon is optimistic about its prospects for the year ahead with potential growth of products across a range of fronts, including pharmaceuticals and electronics.

“It’s a very strong year for us,” says Roger Viney, global sales director for Hovione (Loures, Portugal), a mid-size, privately owned, pharma fine chemicals group. The company has a “strong order book.” Sales for this year are about 15% up on the past year, Viney says. The company’s business is split evenly between generic and original brand drug activies. Hovione is gaining customers that previously would have been sourcing product in Asia but now consider quality to be a high priority, Viney says.

Meanwhile, Mark Griffiths, CEO of Codexis, warns that the contract fine chemicals sector could be about to see a period of consolidation. “It’s tough out there,” he says. In particular venture capital money for biotech start-ups is now harder to secure and this is having a knock-on effect across the pharma contract manufacturing sector, Griffiths said.

Griffiths rejoined Carbogen in recent months after a few years away from the company and has immediately implemented a restructure to reduce the company’s cost base, improving efficiency across the business and refocusing the company’s activities so that it can better deliver for its customers. To further reduce costs, Carbogen-Amcis will work more closely with its parent company Dishman Group (Ahmedabad, India) in areas such as sourcing of raw materials and early phase intermediates, Griffiths says. Carbogen-Amcis is looking further down the value chain for areas where it can make acquisitions or collaborations, he says.

Carbogen-Amcis has an extensive offering in areas such as high potency active pharma (HPAPI) production as well as in chromatography. The company is set to become more reactive to customer needs and more entrepreneurial in its approach as a result of its recent restructure, Griffiths says. Carbogen-Amcis has a goal of making a profit this year andl then to secure double-digit percentage sales growth during 2012.

“I am surprised that there has not been any consolidation. I am surprised that there are so many [companies] working in the CMO [contract manufacturing organization] space,” Griffiths says. “It’s good to have competition but I am not sure how long this industry can be sustained.”

Gilles Cottier SAFC’s president also senses a period of consolidation, in part because between 2012 and 2016 original patented drugs with sales in the order of $120 billion will come off patent. “That’s a huge volume of revenue [for our customers] that is going to evaporate. This is why it’s going to be different,” Cottier says. “I don’t think we’ll see the market will grow significantly in the next five years. This will signal the end for a number of assets because not everyone will be able to survive,” Cottier says. SAFC, which operates predominantly in niche activities such as HPAPI production, predicts that it will secure high single-digit percentage sale growth for this year.

http://www.chemweek.com/home/top_of_the_news/38529.html

“We continue to see significant demand for our HFIP and HFIP-derived compounds. With the increasing number of applications and end-products that incorporate HFIP, we expect this trend to continue,” Murin says.
 
Halocarbon also has continued to grow on other fronts. Advancements and recent pilot plant scale-ups have focused on electronics chemicals and its existing trifluoro-based line, which remains strong worldwide. “We continue to see strong sales of our TFA, TFAA, and TFAC to the pharmaceutical, agriculture, and industrial areas,” says Ron Epstein, director/sales. “We have upgraded our TFA and TFAA production, which has given us additional capacity to meet our customers’ requirements. We’re also experiencing strong worldwide sales of our inert oils, greases, and waxes.”
 
Halocarbon has also grown in the coatings area, supplying HFA monomers to the semiconductor and specialty coatings market.
 
Looking further ahead, the company has started research into direct fluorination projects and is pursuing collaborations with other companies to explore opportunities for additional high-value products.

Halocarbon (River Edge, NJ) has carved out a profitable niche in fluorine chemistry, leveraging 60 years of expertise to build positions in specialty fluorochemicals, inhalation anesthetics, and inert oils, waxes, and greases. The privately held company does not disclose sales, but says revenues are in the tens of millions of dollars per year. Growth has been strong, at 20% in 2010, due to the addition of new chemistries, and early indications show the company is on track to post similar results for full-year 2011. Fluorochemicals make up about half of Halocarbon’s sales, with anesthetics and oils, greases, and waxes accounting for the remaining 30% and 20%, respectively. Exports accounted for just under 60% of the company’s revenue last year.

Robert Ehrenfeld founded the company in 1950 based on inert fluorinated lubricants technology he developed for the Manhattan Project, the U.S. effort to build an atom bomb during World War II. Since his death in 2007, the company has been owned by Ehrenfeld’s three daughters, including president Emily Ehrenfeld. In the late 1950s, the company leveraged know-how in fluorochemicals to add trifluoroacetyl chloride (TFAC) derivatives. It currently produces inhalation anesthetic isoflurane from trifluoroacetic acid. Another TFAC derivative, trifluoroacetamide, is used in the pain drug celcoxib. The company is currently sold out of TFAC derivatives.

Halocarbon expanded into hexafluoroacetone (HFA) and HFA derivatives to continue to serve an inhalation anesthetic market that was migrating to sevoflurane, a product developed by Baxter Laboratories. Halocarbon began selling sevoflurane in 2008. The company says it has been inundated with requests for HFA derivatives for a number of other specialty applications. These small volumes require extremely high purity and can cost thousands of dollars per kg, says Ron Epstein, sales director/Halocarbon.

Demand has been so strong that the company has been selective about HFA opportunities. “The world seems to have been somewhat under-served in HFA derivatives, based on the volume of the inquiries we’re receiving,” says CEO Peter Murin. For many of these chemistries, Halocarbon’s only competitor is Central Glass (Tokyo).

Customers have been requesting increasingly complex molecules in applications where fluorochemicals have not yet been prevalent, says Barry Jones, technical director. Photoresist makers have been using HFA derivatives in coatings, an application that is expected to be Halocarbon’s fastest-growing for the near future. Requests from pharmaceutical companies are also increasing, and some customers are experimenting with HFA derivatives in medical device coatings.

Strong demand has caused a crunch at Halocarbon’s sole manufacturing site at North Augusta, SC. The company does not disclose production capacity details, but says it is planning a “significant” debottlenecking in the HFA portion of the plant. However, Murin expects debottlenecking opportunities to run out within a year. The company is not planning a second facility at North Augusta in the near term. “Volumes for our current portfolio don’t support such an investment,” Murin says. “An additional plant would only be supported by a decision to enter a new area of fluorochemicals.” However, no such decision is in the works.

The company became averse to high-volume products ten years ago, when competitors for its TFAC business began to emerge in Asia, Murin says. “We now tend to shy away from customer requests for products in the thousands of metric tons.” Halocarbon has, for example, turned away opportunities in agrochemicals. “The products would have been high-volume applications, but also in a more competitive, low-margin situation. We like to focus on high-value product requests of 100 m.t. or even 10 m.t.”

Whether or not a chemical can be easily made by competitors is also a factor in whether or not Halocarbon will take on a project. “If it’s a commodity product and a lot of companies can produce it, then it’s just not for us,” Epstein says.

Murin theorizes larger chemical companies with fluorochemical expertise, such as DuPont, do not find the low-volume applications pursued by Halocarbon interesting enough to attract investment. “One million dollars per year profit growth is sizable to us, but to a company like DuPont or Dow it’s not enough to get excited about.” Dedication to being a true niche player has helped the company ride out market volatility, Murin says. During the recession, none of Halocarbon’s 150 employees were laid off.

Although HFA derivative sales growth is outpacing TFAC, Murin says the TFAC side is still active. Demand is growing for trifluoroacetic acid for use in glass coatings, and the company recently learned one of its customers is using it in solar panels. While Halocarbon has been producing many of its oils, greases, and waxes for 60 years, the business “is far from a dead product group,” Epstein says. Volumes are moderate, but demand and profits remain steady, and for many applications, materials with similar properties have never been developed. The company’s oils are used in applications ranging from missile guidance systems to fruit fly breeding in biological research. The company’s greases have recently begun to be used for pipe connections in hydraulic fracturing applications, and its waxes are used as a barrier coating against corrosive chemicals.

http://www.chemweek.com/sections/companies/34128.html

BASF custom synthesis business has been unaffected by the global economic uncertainty. “In general we see this as a growing market,” says Folker Ruchatz, v.p./global business management custom synthesis at BASF. The company is experiencing “steady growth” in activities relating to generic APIs, with “stronger growth” for excipients, especially in high-performance and innovative products. The company also is experiencing “strong demand” in custom synthesis, where Ruchatz predicts BASF “will grow faster than the market. We have a positive outlook for 2012,” he says. Although BASF doesn’t split out the financial performance of its pharmaceutical fine chemicals activities the business is among the top-10 players in the world, Ruchatz says.

Codexis (Redwood City, CA), an enzymes technology firm, since 2010 has increased its pharma customers from about 15 to about 50. In part this growth has come about because the company has changed its patent position by allowing its customers to patent processes using Codexis’s insights. The growth is also down to a greater acceptance across the pharma industry of using biocatalysis, says Peter Seufer-Wasserthal, v.p. and managing director/pharma services for Codexis. “Financials are good, the order book is on the full side,” Seufer-Wasserthal says.

Halocarbon (River Edge, NJ),a fluorochemicals pure play, also is experiencing year-on-year growth and is optimistic about its prospects for 2012. Quality is pinpointed by the company as a factor that is contributing to its growth. An illustration of its quality management is the company decision to appoint a dedicated inspector of labels on products. The company photographs every shipment of a product so that it knows that the product is going out in good order. “This [kind of] a detail we feel is being recognized,” says Ron Epstein, director/sales for Halocarbon. Halocarbon is optimistic about its prospects for the year ahead with potential growth of products across a range of fronts, including pharmaceuticals and electronics.

“It’s a very strong year for us,” says Roger Viney, global sales director for Hovione (Loures, Portugal), a mid-size, privately owned, pharma fine chemicals group. The company has a “strong order book.” Sales for this year are about 15% up on the past year, Viney says. The company’s business is split evenly between generic and original brand drug activies. Hovione is gaining customers that previously would have been sourcing product in Asia but now consider quality to be a high priority, Viney says.Meanwhile, Mark Griffiths, CEO of Codexis, warns that the contract fine chemicals sector could be about to see a period of consolidation. “It’s tough out there,” he says. In particular venture capital money for biotech start-ups is now harder to secure and this is having a knock-on effect across the pharma contract manufacturing sector, Griffiths said.

Griffiths rejoined Carbogen in recent months after a few years away from the company and has immediately implemented a restructure to reduce the company’s cost base, improving efficiency across the business and refocusing the company’s activities so that it can better deliver for its customers. To further reduce costs, Carbogen-Amcis will work more closely with its parent company Dishman Group (Ahmedabad, India) in areas such as sourcing of raw materials and early phase intermediates, Griffiths says. Carbogen-Amcis is looking further down the value chain for areas where it can make acquisitions or collaborations, he says.

Carbogen-Amcis has an extensive offering in areas such as high potency active pharma (HPAPI) production as well as in chromatography. The company is set to become more reactive to customer needs and more entrepreneurial in its approach as a result of its recent restructure, Griffiths says. Carbogen-Amcis has a goal of making a profit this year andl then to secure doubledigit percentage sales growth during 2012.

“I am surprised that there has not been any consolidation. I am surprised that there are so many [companies] working in the CMO [contract manufacturing organization] space,” Griffiths says. “It’s good to have competition but I am not sure how long this industry can be sustained.”

Gilles Cottier SAFC’s president also senses a period of consolidation, in part because between 2012 and 2016 original patented drugs with sales in the order of $120 billion will come off patent. “That’s a huge volume of revenue [for our customers] that is going to evaporate. This is why it’s going to be different,” Cottier says. “I don’t think we’ll see the market will grow significantly in the next five years. This will signal the end for a number of assets because not everyone will be able to survive,” Cottier says. SAFC, which operates predominantly in niche activities such as HPAPI production, predicts that it will secure high single-digit percentage sale growth for this year.

Robert Ehrenfeld founded the company in 1950 based on inert fluorinated lubricants technology he developed for the Manhattan Project, the U.S. effort to build an atom bomb during World War II. Since his death in 2007, the company has been owned by Ehrenfeld’s three daughters, including president Emily Ehrenfeld. In the late 1950s, the company leveraged know-how in fluorochemicals to add trifluoroacetyl chloride (TFAC) derivatives. It currently produces inhalation anesthetic isoflurane from trifluoroacetic acid. Another TFAC derivative, trifluoroacetamide, is used in the pain drug celcoxib. The company is currently sold out of TFAC derivatives.

Halocarbon expanded into hexafluoroacetone (HFA) and HFA derivatives to continue to serve an inhalation anesthetic market that was migrating to sevoflurane, a product developed by Baxter Laboratories. Halocarbon began selling sevoflurane in 2008. The company says it has been inundated with requests for HFA derivatives for a number of other specialty applications. These small volumes require extremely high purity and can cost thousands of dollars per kg, says Ron Epstein, sales
director/Halocarbon.

Demand has been so strong that the company has been selective about HFA opportunities. “The world seems to have been somewhat under-served in HFA derivatives, based on the volume of the inquiries we’re receiving,” says CEO Peter Murin. For many of these chemistries, Halocarbon’s only competitor is Central Glass (Tokyo).

Customers have been requesting increasingly complex molecules in applications where fluorochemicals have not yet been prevalent, says Barry Jones, technical director. Photoresist makers have been using HFA derivatives in coatings, an application that is expected to be Halocarbon’s fastest-growing for the near future. Requests from pharmaceutical companies are also increasing, and some customers are experimenting with HFA derivatives in medical device coatings.

Strong demand has caused a crunch at Halocarbon’s sole manufacturing site at North Augusta, SC. The company does not disclose production capacity details, but says it is planning a “significant” debottlenecking in the HFA portion of the plant. However, Murin expects debottlenecking opportunities to run out within a year. The company is not planning a second facility at North Augusta in the near term. “Volumes for our current portfolio don’t support such an investment,” Murin says. “An additional plant would only be supported by a decision to enter a new area of fluorochemicals.” However, no such decision is in the works.

The company became averse to high-volume products ten years ago, when competitors for its TFAC business began to emerge in Asia, Murin says. “We now tend to shy away from customer requests for products in the thousands of metric tons.” Halocarbon has, for example, turned away opportunities in agrochemicals. “The products would have been high-volume applications, but also in a more competitive, low-margin situation. We like to focus on high-value product requests of 100 m.t. or even 10 m.t.”

Whether or not a chemical can be easily made by competitors is also a factor in whether or not Halocarbon will take on a project.

“If it’s a commodity product and a lot of companies can produce it, then it’s just not for us,” Epstein says.

Murin theorizes larger chemical companies with fluorochemical expertise, such as DuPont, do not find the low-volume applications pursued by Halocarbon interesting enough to attract investment. “One million dollars per year profit growth is sizable to us, but to a company like DuPont or Dow it’s not enough to get excited about.” Dedication to being a true niche player has helped the company ride out market volatility, Murin says. During the recession, none of Halocarbon’s 150 employees were laid off.

Although HFA derivative sales growth is outpacing TFAC, Murin says the TFAC side is still active. Demand is growing for trifluoroacetic acid for use in glass coatings, and the company recently learned one of its customers is using it in solar panels. While Halocarbon has been producing many of its oils, greases, and waxes for 60 years, the business “is far from a dead product group,” Epstein says. Volumes are moderate, but demand and profits remain steady, and for many applications, materials with similar properties have never been developed. The company’s oils are used in applications ranging from missile guidance systems to fruit fly breeding in biological research. The company’s greases have recently begun to be used for pipe connections in hydraulic fracturing applications, and its waxes are used as a barrier coating against corrosive chemicals.

Worldwide supply of hexafluoroisopropanol (HFIP), a compound used in photoresists for semiconductor manufacturing as well asin the anesthetic sevoflurane, is very tight. To meet the increase in demand Halocarbon has upgraded its plant to increasecapacity and “fill the void,” the company says.

The shortage is caused by demand for HFIP raw materials being used for otherproducts, namely R1234yf refrigerant and fluoroelastomers, the company says.“We continue to see significant demand for our HFIP and HFIP-derived compounds. With the increasing number of applicationsand end-products that incorporate HFIP, we expect this trend to continue,” Murin says.

Halocarbon also has continued to grow on other fronts. Advancements and recent pilot plant scale-ups have focused onelectronics chemicals and its existing trifluoro-based line, which remains strong worldwide. “We continue to see strong sales ofour TFA, TFAA, and TFAC to the pharmaceutical, agriculture, and industrial areas,” says Ron Epstein, director/sales. “We haveupgraded our TFA and TFAA production, which has given us additional capacity to meet our customers’ requirements. We’re alsoexperiencing strong worldwide sales of our inert oils, greases, and waxes.”

Halocarbon has also grown in the coatings area, supplying HFA monomers to the semiconductor and specialty coatings market.

Looking further ahead, the company has started research into direct fluorination projects and is pursuing collaborations with othercompanies to explore opportunities for additional high-value products.

“We’re expecting another year of double-digit growth,” said Halocarbon Chief Executive Officer Peter Murin.

While the worldwide hexafluoroisopropanol (HFIP) supply is very tight, Halocarbon has upgraded its plant to increase HFIP production to fill the void. The shortage is caused by demand for HFIP raw materials being used for other products, namely R1234yf refrigerant and fluoroelastomers.

“We continue to see significant demand for our HFIP and HFIP-derived compounds,” said Murin. “With the increasing number of applications and end-products that incorporate HFIP, we expect this trend to continue.”

Halocarbon has continued to grow on other fronts, as well. Advancements and recent pilot plant scale-ups have focused on electronics chemicals and its existing trifluorobased line, which remains strong worldwide.

“We continue to see strong sales of our TFA, TFAA, and TFAC to the pharmaceutical, agriculture, and industrial areas,” says Ron Epstein. “We have upgraded our TFA and TFAA production, which has given us additional capacity to meet our customers’ requirements. We’re also experiencing strong worldwide sales of our inert oils, greases,
and waxes.”

Halocarbon has also grown in the coatings area, supplying HFA monomers to the semiconductor and specialty coatings market.

Looking ahead, the company is beginning research into carrying out direct fluorination and pursuing projects involving collaborations with other companies – furthering its goal of constantly exploring opportunities to create more high-value products.

About Halocarbon
With headquarters in River Edge, New Jersey, and a state-of-the-art manufacturing plant in North Augusta, South Carolina, USA, Halocarbon is one of the world’s leading producers of specialty fluorochemicals. Halocarbon products include inert lubricants, aliphatic fluorochemicals for pharmaceutical and agricultural chemical manufacturing,
inhalation anesthetics, and other specialty products. For more information, please contact the company at +1-201-262-8899 or at www.halocarbon.com

River Edge, NJ – April 19, 2011 – Halocarbon Products Corporation, a leading worldwide producer of specialty fluorochemicals, has hired Anthony Nigro as an Account Manager. He will be responsible for Halocarbon’s inert lubricants business segment and developing its specialty coatings and electronics fluorochemicals businesses.

Nigro has more than 10 years experience in the chemical industry, serving previously as a technical sales representative with Gattefosse, a medicinal chemist with Astellas (formerly OSI Pharmaceuticals) where he worked on multiple projects that led to several publications and patents, and a senior scientist with Roche Pharmaceuticals in its chemical synthesis group. In addition, Nigro gained experience in procurement with Roche Pharmaceuticals as a sourcing manager supporting the company’s research, development and marketing.

“We’re excited to add Anthony to our growing sales and marketing team,” said Ron Epstein, sales director for Halocarbon. “His experience, knowledge and strong industry relationships make him an immediate asset to Halocarbon and our customers.”

An honors graduate of State University of New York at Oswego with a Bachelor of Science degree in Chemistry, Nigro continued his education at State University of New York Stony Brook and achieved his Master of Science degree in Organic Chemistry.

About Halocarbon
With headquarters in River Edge, New Jersey, and a state-of-the-art manufacturing plant in North Augusta, South Carolina, USA, Halocarbon is one of the world’s leading producers of specialty fluorochemicals. Halocarbon products include inert lubricants, aliphatic fluorochemicals for pharmaceutical and agricultural chemical manufacturing, inhalation anesthetics and other specialty products. For more information, please contact the company at +1-201-262-8899 or at www.halocarbon.com.

River Edge, NJ – Halocarbon Products Corporation, a leading worldwide producer of specialty fluorochemicals and inhalation anesthetics celebrating 60 years in business this year, has seen its sales rise in 2010, a sign of growing economic confidence from customers around the world.

“We’re pleased that our sales are up over last year and that confidence is returning,” said Peter Murin, Halocarbon CEO. “Even more encouraging than the sales increase is the large number of inquiries we’ve been receiving for new compounds. That tells us that companies are optimistic about the future and are back to innovating again after a couple of tough years.”

The company is completing a rework of its website to make it easier for existing and new customers to identify how Halocarbon can help them with their needs. The updated site is expected to launch during CPhI 2010. “With our ever-increasing library of innovative fluorochemicals and a full pipeline of new compounds, we’ve reorganized our site so visitors can more easily see what we can do,” said Murin.

Recent Product Innovations

The company continues its strength in process development and is pleased to now offer 1,1,1-trifluoroacetone, and its derivatives, which are important building blocks for producing fluorinated compounds that have applications in the pharmaceutical, agrochemical and photolithography fields.

The protons on 1,1,1-trifluoroacetone are more acidic compared to acetone, and thus, relatively mild basic conditions are required to make the enolate of trifluoroacetone. This makes the molecule ideal for use to prepare molecules of interest containing a CF3 group, for example, by using a carbon-carbon bond forming reaction like the aldol condensation. Some recent examples in the patent literature where 1,1,1-trifluoroacetone has been used to prepare compounds having applications in pharmaceutical and photolithography fields include:

Histone deacetylase inhibitors based on trihalomethylcarbonyl compounds
U.S. Pat. No. 7,193,105

Lithographic photoresist composition and process for its use
U.S. Pat. No. 6,730,452

In addition to 1,1,1-trifluoroacetone, Halocarbon is pleased to also offer the following trifluoroacetone derivatives.

• 3-Bromo-1,1,1-trifluoroacetone
• 3,3-Dibromo-1,1,1-trifluoroacetone
• 3-Chloro-1,1,1-trifluoroacetone
• 3,3-Dichloro-1,1,1-trifluoroacetone

The brominated derivative of trifluoroacetone has recently been used in the synthesis of novel benzimidazole compounds that have shown promise for use in prophylaxis or treatment of cancer.

Substituted benzimidazoles and methods of preparation
U.S. Pat. No. 7,767,820

Trifluoroethylamine

Trifluoroethylamine is an important building block for the synthesis of fluorinated nitrogen containing molecules that have proven to be versatile intermediates for the synthesis of compounds with useful properties in both agrochemical and pharmaceutical fields. Some examples from the recent patent literature are shown below.

Fused tricyclic mGluR1 antagonists as therapeutic agents
U.S. Pat. No. 7,767,815

Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses
U.S.Pat. No. 7,799,913

Trifluoropropanoyl Chloride

Halocarbon recently introduced a C3 fluorinated derivative trifluoropropanoyl chloride. This molecule is a useful intermediate in synthesis of compounds with interesting biological activity; an example is shown below.

Aminopyridines useful as kinase inhibitors
U.S. Pat. No. 7,767,672

“All of these compounds provide useful applications in the agrochemical, pharmaceutical and photolithography fields,” said Murin. “We also have a number of compounds in the pipeline. The combination of our technology, culture of quality, superior process development and responsible manufacturing at our plant in South Carolina delivers a powerful package to our customers.”

Halocarbon is a member of the American Chemistry Council (ACC), and actively participates in the ACC’s Responsible Care® initiative, providing further assurance that the company is actively engaged in providing its employees and the neighborhoods in which they work and do business with the safest possible environment.

About Halocarbon
With headquarters in River Edge, New Jersey, and a state-of-the-art manufacturing plant in North Augusta, South Carolina, USA, Halocarbon is one of the world’s leading producers of specialty fluorochemicals. Halocarbon products include inert lubricants, aliphatic fluorochemicals for pharmaceutical and agricultural chemical manufacturing, inhalation anesthetics and other specialty products. For more information, please contact the company at +1-201-262-8899 or at www.halocarbon.com.

Read the full article in Chemical Week.